Quelles sont les conséquences d'une inhibition des MAP kinases ?
L'inhibition peut entraîner des effets indésirables comme une immunosuppression ou des troubles de la croissance.
InhibitionImmunosuppression
Facteurs de risque
5
#1
Quels facteurs de risque sont associés aux troubles des MAP kinases ?
Des facteurs incluent des prédispositions génétiques, l'exposition à des toxines et le stress.
Facteurs de risquePrédispositions génétiques
#2
Le mode de vie influence-t-il les risques liés aux MAP kinases ?
Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques.
Mode de vieAlimentation
#3
L'âge est-il un facteur de risque pour les troubles des MAP kinases ?
Oui, le vieillissement peut affecter la signalisation des MAP kinases et augmenter les risques.
ÂgeVieillissement
#4
Les infections peuvent-elles influencer les MAP kinases ?
Certaines infections peuvent activer les MAP kinases, contribuant à des maladies inflammatoires.
InfectionsMaladies inflammatoires
#5
Le tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?
Oui, le tabagisme peut altérer la signalisation des MAP kinases et augmenter le risque de cancer.
TabagismeCancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Système de signalisation des MAP kinases : Questions médicales les plus fréquentes",
"headline": "Système de signalisation des MAP kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Système de signalisation des MAP kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-26",
"dateModified": "2026-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Transduction du signal",
"url": "https://questionsmedicales.fr/mesh/D015398",
"about": {
"@type": "MedicalCondition",
"name": "Transduction du signal",
"code": {
"@type": "MedicalCode",
"code": "D015398",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.835"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases",
"alternateName": "MAP Kinase Signaling System",
"code": {
"@type": "MedicalCode",
"code": "D020935",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David S Waddell",
"url": "https://questionsmedicales.fr/author/David%20S%20Waddell",
"affiliation": {
"@type": "Organization",
"name": "University of North Florida, Department of Biology, 1 UNF Drive, Jacksonville, FL 32224, USA. Electronic address: d.s.waddell@unf.edu."
}
},
{
"@type": "Person",
"name": "Yuelin Zhang",
"url": "https://questionsmedicales.fr/author/Yuelin%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Botany, University of British Columbia, Vancouver, BC, Canada."
}
},
{
"@type": "Person",
"name": "Emmanuel Prikas",
"url": "https://questionsmedicales.fr/author/Emmanuel%20Prikas",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "Arne Ittner",
"url": "https://questionsmedicales.fr/author/Arne%20Ittner",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "T S Keshava Prasad",
"url": "https://questionsmedicales.fr/author/T%20S%20Keshava%20Prasad",
"affiliation": {
"@type": "Organization",
"name": "Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. keshav@yenepoya.edu.in."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Links between oral microbiome and insulin resistance: Involvement of MAP kinase signaling pathway.",
"datePublished": "2023-07-12",
"url": "https://questionsmedicales.fr/article/37442534",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biochi.2023.06.013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Stretching the limits of extracellular signal-related kinase (ERK) signaling - Cell mechanosensing to ERK activation.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37574635",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ceb.2023.102217"
}
},
{
"@type": "ScholarlyArticle",
"name": "c-Jun N-terminal kinase signaling in cellular senescence.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37335314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00204-023-03540-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1.",
"datePublished": "2023-10-20",
"url": "https://questionsmedicales.fr/article/37883895",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2023.115889"
}
},
{
"@type": "ScholarlyArticle",
"name": "The ERBB2 Exonic Variant Pro1170Ala Modulates Mitogen-Activated Protein Kinase Signaling Cascades and Associates with Allergic Asthma.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37336194",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000530960"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Transduction du signal",
"item": "https://questionsmedicales.fr/mesh/D015398"
},
{
"@type": "ListItem",
"position": 4,
"name": "Système de signalisation des MAP kinases",
"item": "https://questionsmedicales.fr/mesh/D020935"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Système de signalisation des MAP kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Système de signalisation des MAP kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Système de signalisation des MAP kinases",
"description": "Comment diagnostiquer une dysrégulation des MAP kinases ?\nQuels tests sont utilisés pour évaluer les MAP kinases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux MAP kinases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Système de signalisation des MAP kinases",
"description": "Quels symptômes indiquent une activation anormale des MAP kinases ?\nLes troubles neurologiques sont-ils liés aux MAP kinases ?\nComment les MAP kinases affectent-elles le cancer ?\nLes maladies auto-immunes sont-elles liées aux MAP kinases ?\nQuels signes cliniques sont associés à une inflammation chronique ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Système de signalisation des MAP kinases",
"description": "Peut-on prévenir les troubles liés aux MAP kinases ?\nLes examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?\nL'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?\nComment le stress influence-t-il les MAP kinases ?\nLes vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Système de signalisation des MAP kinases",
"description": "Quels traitements ciblent les MAP kinases dans le cancer ?\nLes thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?\nComment les anti-inflammatoires affectent-ils les MAP kinases ?\nLes traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?\nQuels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Système de signalisation des MAP kinases",
"description": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?\nLes troubles cardiovasculaires sont-ils liés aux MAP kinases ?\nComment les MAP kinases sont-elles impliquées dans le diabète ?\nLes maladies neurodégénératives sont-elles liées aux MAP kinases ?\nQuelles sont les conséquences d'une inhibition des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Système de signalisation des MAP kinases",
"description": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?\nLe mode de vie influence-t-il les risques liés aux MAP kinases ?\nL'âge est-il un facteur de risque pour les troubles des MAP kinases ?\nLes infections peuvent-elles influencer les MAP kinases ?\nLe tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des MAP kinases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent aider à identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les MAP kinases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'immunoblotting et la cytométrie en flux pour mesurer l'activité."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies peuvent être nécessaires pour évaluer l'expression des MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux MAP kinases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme ERK, JNK et p38 sont souvent analysés dans les études."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à visualiser des tumeurs, mais ne cible pas directement les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation anormale des MAP kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure inflammation, douleur et croissance cellulaire anormale."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux MAP kinases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements des MAP kinases peuvent contribuer à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases affectent-elles le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive des MAP kinases peut favoriser la prolifération tumorale."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles liées aux MAP kinases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent exacerber les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une inflammation chronique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rougeur, chaleur, gonflement et douleur sont des signes d'inflammation chronique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux MAP kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter certains médicaments peut réduire le risque de dysrégulation des MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il les MAP kinases ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut activer les MAP kinases, contribuant à des maladies."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent moduler la réponse immunitaire via les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les MAP kinases dans le cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des MAP kinases, comme les inhibiteurs de MEK, sont utilisés."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut potentiellement corriger des mutations affectant les MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils les MAP kinases ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent inhiber l'activation des MAP kinases, réduisant l'inflammation."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements ciblés montrent des résultats prometteurs dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, éruptions cutanées et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent le cancer, des maladies inflammatoires et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles cardiovasculaires sont-ils liés aux MAP kinases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une signalisation anormale des MAP kinases peut contribuer à des troubles cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases sont-elles impliquées dans le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAP kinases régulent le métabolisme du glucose, et leur dysfonction peut aggraver le diabète."
}
},
{
"@type": "Question",
"name": "Les maladies neurodégénératives sont-elles liées aux MAP kinases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent être impliquées dans ces maladies."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une inhibition des MAP kinases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inhibition peut entraîner des effets indésirables comme une immunosuppression ou des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs incluent des prédispositions génétiques, l'exposition à des toxines et le stress."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques liés aux MAP kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la signalisation des MAP kinases et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles influencer les MAP kinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent activer les MAP kinases, contribuant à des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la signalisation des MAP kinases et augmenter le risque de cancer."
}
}
]
}
]
}
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. keshav@yenepoya.edu.in.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Proteomics and Metabolomics Core, Department of Molecular Oncology, and Department of Tumor Biology, Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Publications dans "Système de signalisation des MAP kinases" :
Neurobiology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan. Electronic address: touqeer.ahmed@asab.nust.edu.pk.
Publications dans "Système de signalisation des MAP kinases" :
Oral dysbiosis contributes to periodontitis and has implications for systemic diseases. Diabetes mellitus is a common metabolic disorder characterized by impaired glucose regulation. AMP-activated pro...
Extracellular signal-regulated kinase (ERK) has been recognized as a critical regulator in various physiological and pathological processes. Extensive research has elucidated the signaling mechanisms ...
Cellular senescence leads to decreased tissue regeneration and inflammation and is associated with diabetes, neurodegenerative diseases, and tumorigenesis. However, the mechanisms of cellular senescen...
Apoptosis signal regulated kinase 1 (ASK1, also known as MAP3K5) is a member of the mitogen activated protein kinase kinase kinase (MAP3K) family. Since its first isolation from a human macrophage lib...
Previous studies have indicated the ERBB2 genetic variants in the 17q12 locus might be associated with asthma; however, the functional effects of these variants on asthma risk remain inconclusive. Thi...
This study belongs to a part of an ongoing Singapore/Malaysia cross-sectional genetics and epidemiological study (SMCSGES). Genotype-phenotype associations were assessed by performing a genotyping ass...
The ERBB2 tag-SNP rs1058808 was significantly associated with allergic asthma, with the allele "G" identified as protective against the disease (adjusted logistic p = 6.56 × 10-9, OR = 0.625, 95% CI: ...
The present findings highlighted the involvement of a functional exonic variant of ERBB2 in asthma development via modulating the MAPK signaling cascade....
Lysophosphatidic acid (LPA) is a well-documented pro-oncogenic factor in different cancers, but relatively little is known on its biological activity in neuroblastoma. The LPA effects and the particip...
This study aimed to investigate BVD-523 (ulixertinib), an adenosine triphosphate (ATP)-dependent extracellular signal-regulated kinases 1/2 inhibitor, for its antitumor potential in thyroid cancer....
Ten thyroid cancer cell lines known to carry mitogen-activated protein kinase (MAPK)-activated mutations, including v-Raf murine sarcoma viral oncogene homolog B (BRAF) and rat sarcoma virus (RAS) mut...
BVD-523 significantly inhibited thyroid cancer cell proliferation and induced G1/S cell cycle arrest dose-dependently. Notably, cell lines carrying MAPK mutations, especially those with the BRAF V600E...
This study reveals the potent antitumor activity of BVD-523 against thyroid cancer cells bearing MAPK-activating mutations, offering promise for treating aggressive forms of thyroid cancer....
The alterations of EGFR and HER2/neu as growth factor receptors and the cytoplasmic signal transduction proteins of RAS/RAF/MAP kinases including its end effector molecule (ERK) are important in the c...
Immunohistochemistry- using tissue microarrays- for EGFR, HER2/neu, non-phosphorylated, and phosphor-ERK, was performed on tissues from 166 patients- with primary prostatic adenocarcinoma with no prio...
The prostatic tissue showed EGFR, HER2 neu, phosphorylated and non-phosphorylated ERK expression in 8.4%, 1.4%, 78.2%, and 83.4% respectively whether low (patchy) or high expression (diffuse). There w...
EGFR and HER2/neu may play a limited role in prostatic adenocarcinoma as they showed positive expression in a limited number of the examined tissues specifically HER2neu. The expression of non-phospho...
Cannabidiol exerts its anti-inflammatory and anti-oxidant activities in various human cells. However, its proliferative effect has not been extrapolated to human gingival fibroblasts (HGFs). This stud...
HGFs, characterized by their CD73, CD90, and CD105 expressions by flow cytometry, were treated with cannabidiol at 0.01-30 μM. The cytotoxicity was determined by the MTT assay, while the proliferative...
No toxicity was found in HGFs treated with any doses of cannabidiol up to 30 μM. The mean percentage of cell proliferation was significantly enhanced by treatment with cannabidiol at 3 or 10 μM (p < ....
Treatment with cannabidiol at non-toxic doses promotes HGFs' proliferation and migration....
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy with poor prognosis and dismal patient survival. Although protein kinase D (PKD) isoforms, especially PKD2 and PKD3 are cri...